Aurora Labs Applies to Quote 81,990,081 Ordinary Shares at $0.055 Issued 6 November 2026

Aakashdeep

06 November 2026 11:23 AM AEDT

Aurora Labs Applies to Quote 81,990,081 Ordinary Shares at $0.055 Issued 6 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Aurora Labs Limited (ASX:A3D) has lodged an Appendix 2A application for the quotation of 81,990,081 fully paid ordinary shares, issued on 6 November 2026 at a price of AUD $0.055 per security, as part of a placement transaction previously announced to the market on 28 October 2026.

Key Points

81,990,081 ordinary fully paid shares to be quoted on ASX, issued on 6 November 2026 at AUD $0.055 each
Securities form part of a placement previously disclosed via an Appendix 3B lodged on 28 October 2026
A further 7,500,000 options remain to be issued to complete the transaction referenced in the Appendix 3B
Total quoted ordinary shares in A3D will reach 605,609,737 following quotation of the new securities

Placement Details and Issue Terms

The 81,990,081 ordinary fully paid shares were issued for cash consideration in Australian dollars at an issue price of AUD $0.055 per security. The filing confirms the issue date as 6 November 2026. The securities form part of a placement or other type of issue that was previously notified to ASX via an Appendix 3B lodged on 28 October 2026 at 09:34. Aurora Labs Limited holds an ABN of 44 601 164 505 and is listed on the ASX under the issuer code A3D.

Further Securities Yet to Be Issued Under the Transaction

According to the filing, the transaction referenced in the 28 October 2026 Appendix 3B has not been fully completed by this quotation application. Aurora Labs disclosed that a further 7,500,000 options are yet to be issued to complete the transaction. No additional details regarding the terms of those options, including exercise price or expiry date, were provided in this filing in relation to the forthcoming issue.

Issued Capital Following Quotation

Following quotation of the 81,990,081 new ordinary shares, Aurora Labs' total quoted ordinary fully paid securities on issue will comprise 605,609,737 shares. The company also holds a range of unquoted securities, including options across multiple series with expiry dates ranging from 2027 to 2029 and exercise prices between $0.078 and $0.15, as well as 1,500,000 performance rights. Among the unquoted classes, the largest single option series is A3DAB, comprising 25,000,000 options expiring 10 April 2028 at an exercise price of $0.14.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.